Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Intravenous Ganciclovir Followed by Oral Ganciclovir in the Treatment of Reactivation of CMV Following Bone Marrow Transplant

NCT00530218 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT00530218
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00530218 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Intravenous Ganciclovir Followed by Oral Ganciclovir in the Treatment of Reactivation of CMV Following Bone Marrow Transplant
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
March 31, 1999
Completion date
February 28, 2010
Enrollment
61 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, lymphoma, mds, multiple myeloma, myelodysplastic/myeloproliferative diseases, myelodysplastic/myeloproliferative neoplasm, unclassifiable